Citius Pharmaceuticals Completes Direct Offering
Citius Pharmaceuticals Inc. (NASDAQ: CTXR), known for its commitment to developing innovative biopharmaceutical solutions, has successfully finalized a registered direct offering. This offering encompassed a total of 12,000,000 shares of common stock, paired with warrants to purchase an equal number of shares. The purchase price was set at $0.25 per share, with accompanying warrants also at the same exercise price.
Details of the Offering
H.C. Wainwright & Co. served as the exclusive placement agent for this offering, ensuring the smooth execution and increased investor confidence. As a result, the gross proceeds from this transaction reached an impressive $3 million, excluding any fees and expenses that will be associated with the placement agent. Citius Pharmaceuticals intends to utilize the net proceeds to bolster various corporate activities. This includes supporting both pre-clinical and clinical development of their key product candidates as well as addressing general working capital needs.
Regulatory Notes
The offering is conducted in accordance with a "shelf" registration statement, which was duly filed and granted effective status by the Securities and Exchange Commission (SEC). The offerings are made solely through a prospectus, including a supplement that details the securities involved. For further details, interested parties can review the prospectus supplement publicly filed with the SEC, as well as reach out directly to H.C. Wainwright & Co. for electronic copies.
About Citius Pharmaceuticals
Citius Pharmaceuticals stands at the forefront of biopharmaceutical innovation, striving to create first-in-class products that cater to the critical care market. A significant milestone occurred when the FDA approved LYMPHIR™, a groundbreaking immunotherapy aimed at treating cutaneous T-cell lymphoma. Additionally, the company’s late-stage pipeline features Mino-Lok, a product aimed at addressing catheter-related bloodstream infections, as well as CITI-002 (Halo-Lido), designed for hemorrhoid relief.
Clinical Developments
In 2023, the pivotal Phase 3 Trial for Mino-Lok yielded promising results, meeting all primary and secondary endpoints. Following these successful trials, Citius Pharmaceuticals is in active discussions with FDA representatives to plan the next steps for both Mino-Lok and Halo-Lido. Furthermore, Citius Pharma maintains a controlling 92% stake in Citius Oncology, Inc., enhancing its strategic position in the oncology sphere.
Future Outlook
The future paths of Citius Pharmaceuticals appear robust as it continues to navigate the complexities of drug approvals and clinical advancements. With a strong financial foundation bolstered by recent funding, the company is well-positioned to further explore its innovative product pipeline. This funding is vital in the biopharmaceutical sector, especially when transitioning from clinical trials to market readiness, where vast resource allocation is necessary.
Frequently Asked Questions
What is the purpose of Citius Pharmaceuticals' recent offering?
The direct offering aims to generate funds for corporate purposes, focusing on the pre-clinical and clinical development of their therapeutics.
Who acted as the placement agent for the offering?
H.C. Wainwright & Co. was the exclusive placement agent for the registered direct offering.
What will the proceeds from the offering be used for?
The net proceeds will support various corporate initiatives, including the development of key product candidates and working capital needs.
Can you explain the status of the shelf registration statement?
The offering is made under a shelf registration statement, which was filed and became effective with the SEC, simplifying the process for public offerings.
What notable product approvals has Citius Pharmaceuticals received?
Citius Pharmaceuticals received FDA approval for LYMPHIR™, an innovative immunotherapy targeting cutaneous T-cell lymphoma.
